Uplizna approval, novel agents usher in ‘transformative time’ for IgG4-related disease

The FDA’s approval of inebilizumab has heralded a new era for patients with IgG4-related disease, while novel agents moving through trials may provide additional hope for patients with this rare and complex disorder, according to experts.“The approval of inebilizumab in 2025 was a landmark moment for IgG4-related disease,” Matthew C. Baker MD, MS, associate division chief in the

Raccontata dahealio.com